ImmunogenicityAllergenic Activity and Preserve Grass Pollen Allergen, Phl p 6, to Reduce Genetic Engineering of the Major Timothy

On the basis of IgE epitope mapping data, we have produced three allergen fragments comprising aa 1–33, 1–57, and 31–110 of the major timothy grass pollen allergen Phl p 6 aa1–110 by expression in Escherichia coli and chemical synthesis. Circular dichroism analysis showed that the purified fragments lack the typical (cid:1) -helical fold of the complete allergen. Superposition of the sequences of the fragments onto the three-dimensional allergen structure indicated that the removal of only one of the four helices had led to the destabilization of the (cid:1) helical structure of Phl p 6. The lack of structural fold was accompanied by a strong reduction of IgE reactivity and allergenic activity of the three fragments as determined by basophil histamine release in allergic patients. Each of the three Phl p 6 fragments adsorbed to CFA induced Phl p 6-specific IgG Abs in rabbits. However, immunization of mice with fragments adsorbed to an adjuvant allowed for human use (AluGel-S) showed that only the Phl p 6 aa 31–110 induced Phl p 6-specific IgG Abs. Anti-Phl p 6 IgG Abs induced by vaccination with Phl p 6 aa31–110 inhibited patients’ IgE reactivity to the wild-type allergen as well as Phl p 6-induced basophil degranulation. Our results are of importance for the design of hypoallergenic allergy vaccines. They show that it has to be demonstrated that the hypoallergenic derivative induces a robust

[1]  R. Esch Grass pollen allergens. , 2020, Clinical allergy and immunology.

[2]  Matthew Plante,et al.  Reduced Allergenic Potency of VR9-1, a Mutant of the Major Shrimp Allergen Pen a 1 (Tropomyosin)1 , 2005, The Journal of Immunology.

[3]  R. Coffman,et al.  Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction , 2005, The Journal of experimental medicine.

[4]  M. Jutel,et al.  Allergen-specific immunotherapy with recombinant grass pollen allergens. , 2005, The Journal of allergy and clinical immunology.

[5]  C. Akdis,et al.  Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1 , 2005, International Archives of Allergy and Immunology.

[6]  Franz König,et al.  Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. , 2005, The Journal of allergy and clinical immunology.

[7]  R. Valenta,et al.  A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. , 2005, The Journal of allergy and clinical immunology.

[8]  D. Wraith,et al.  Peptide-based therapeutic vaccines for allergic and autoimmune diseases , 2005, Nature Medicine.

[9]  S. Ying,et al.  Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  E. Vartiainen,et al.  IgE Reactivity Pattern to Timothy and Birch Pollen Allergens in Finnish and Russian Karelia , 2005, International Archives of Allergy and Immunology.

[11]  P. Bhalla,et al.  Engineered allergens for immunotherapy , 2004, Current opinion in allergy and clinical immunology.

[12]  K Henrick,et al.  Electronic Reprint Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions , 2022 .

[13]  H. Grönlund,et al.  Vaccination with genetically engineered allergens prevents progression of allergic disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Valenta,et al.  Vaccine Engineering Improved by Hybrid Technology , 2004, International Archives of Allergy and Immunology.

[15]  Lee Whitmore,et al.  DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data , 2004, Nucleic Acids Res..

[16]  R. Valenta,et al.  Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 71 , 2004, The Journal of Immunology.

[17]  R. Valenta,et al.  Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1 , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  R. Valenta,et al.  Analysis of the sensitization profile towards allergens in central Africa , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  P. Colombo Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: in vitro and in vivo evaluation. , 2003, Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M.

[20]  R. Valenta,et al.  The FASEB Journal express article 10.1096/fj.01-1012fje. Published online June 21, 2002. , 2022 .

[21]  R. Valenta The future of antigen-specific immunotherapy of allergy , 2002, Nature Reviews Immunology.

[22]  M. Wills-Karp,et al.  Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. , 2002, The Journal of allergy and clinical immunology.

[23]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[24]  Lee Whitmore,et al.  DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra , 2002, Bioinform..

[25]  S. Monasterolo,et al.  Measurement of IgE antibodies against purified grass‐pollen allergens (Phl p 1, 2, 3, 4, 5, 6, 7, 11, and 12) in sera of patients allergic to grass pollen , 2001, Allergy.

[26]  R. Valenta,et al.  Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules. , 2001, The Journal of investigative dermatology.

[27]  R. Valenta,et al.  Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  P. Hufnagl,et al.  Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  A. Kagey‐Sobotka,et al.  Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. , 2001, The Journal of allergy and clinical immunology.

[30]  F. Horak,et al.  A well‐tolerated grass pollen‐specific allergy vaccine containing
a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections , 2001, Allergy.

[31]  R. Valenta,et al.  Recombinant allergen molecules: tools to study effector cell activation , 2001, Immunological reviews.

[32]  C. Suphioglu What are the important allergens in grass pollen that are linked to human allergic disease? , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[33]  B. Haselden,et al.  Peptide-Mediated Immune Responses in Specific Immunotherapy , 2000, International Archives of Allergy and Immunology.

[34]  E. Raz,et al.  Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. , 2000, The Journal of allergy and clinical immunology.

[35]  M. Nadler,et al.  Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function. , 2000, Advances in immunology.

[36]  J. Kinet,et al.  Signalling through the high-affinity IgE receptor FcεRI , 1999, Nature.

[37]  R. Valenta,et al.  Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen. , 1999, Journal of immunology.

[38]  R. Valenta,et al.  Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing. , 1999, The Journal of investigative dermatology.

[39]  P. Bhalla,et al.  Genetically Engineered Plant Allergens with Reduced Anaphylactic Activity , 1999, International Archives of Allergy and Immunology.

[40]  M. Schlaak,et al.  "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. , 1999, Journal of immunology.

[41]  J. Kinet,et al.  Signalling through the high-affinity IgE receptor Fc epsilonRI. , 1999, Nature.

[42]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[43]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[44]  R. Valenta,et al.  Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. , 1998, Journal of immunology.

[45]  C. Akdis,et al.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. , 1998, The Journal of allergy and clinical immunology.

[46]  R. Valenta,et al.  IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. , 1998, The Journal of allergy and clinical immunology.

[47]  R. Valenta,et al.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. , 1997, The Journal of clinical investigation.

[48]  R. Valenta,et al.  Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. , 1996, The Journal of allergy and clinical immunology.

[49]  R. Valenta,et al.  Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. , 1996, The Journal of allergy and clinical immunology.

[50]  C. Dolecek,et al.  Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). , 1996, The Journal of allergy and clinical immunology.

[51]  J. Hughes,et al.  Genetically engineered vaccines. , 1995, American pharmacy.

[52]  M. Schlaak,et al.  Characterization of the allergen group VI in timothy grass pollen (Phl p 6). II. cDNA cloning of Phl p 6 and structural comparison to grass group V. , 1995, International archives of allergy and immunology.

[53]  N L Harris,et al.  Four helix bundle diversity in globular proteins. , 1994, Journal of molecular biology.

[54]  M. Muhm,et al.  Interleukin 3 activates human blood basophils via high-affinity binding sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Fling,et al.  Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. , 1986, Analytical biochemistry.

[56]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[57]  K. Mathews Immunotherapy for allergic disease. , 1976, Comprehensive therapy.

[58]  K. Ishizaka,et al.  Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity wth gamma-E-globulin antibody. , 1966, Journal of immunology.